{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:29:33Z","timestamp":1785428973292,"version":"3.56.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Real-world studies are needed to expand our knowledge concerning populations underrepresented in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the safety and effectiveness of ocrelizumab in Hispanic\/Latino people with multiple sclerosis (pwMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Prospective longitudinal observational study including pwMS who received at least one dose of ocrelizumab between June 2018 and October 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 305 pwMS (223 relapsing\u2013remitting MS (RRMS), 29 secondary progressive MS (SPMS), and 53 primary progressive MS (PPMS)), 67% female, mean age 38.7, mean disease duration 7 years, and median Expanded Disability Status Scale (EDSS) 2.0 (range 0\u20137). Median follow-up under ocrelizumab 29.5 (range 6\u201365) months. Only 1 patient had a relapse, 12-week-confirmed disability worsening was observed in 12.4% of the full cohort. Survival analysis showed higher risk of 12-week-confirmed disability worsening in SPMS compared with RRMS and PPMS (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0009). Magnetic resonance imaging (MRI) activity was significantly reduced from baseline across all disease phenotypes. Serious infections were observed in 4.6%, and two patients died during follow-up (one serious COVID-19 and one metastatic cancer). Notably, 22 pregnancies were reported, with 11 newborns and 6 pregnancies still on course.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study supports the effectiveness of ocrelizumab in a real-world cohort of individuals from traditionally underrepresented groups, such as the Latin American population, with a consistent safety profile in patients receiving care at a specialized MS Unit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585241309835","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:17:57Z","timestamp":1736137077000},"page":"444-454","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9377-8275","authenticated-orcid":false,"given":"Adolfo","family":"del Canto","sequence":"first","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"C\u00e1rcamo","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-8502","authenticated-orcid":false,"given":"Lorena","family":"Garcia","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Aylwin","sequence":"additional","affiliation":[{"name":"Public Health, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Central Metropolitan Health Service, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"J\u00fcrgensen-Heinrich","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Guzman-Carcamo","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"de la Barra","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Gutierrez-Calquin","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Barrera-Hormazabal","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-7273","authenticated-orcid":false,"given":"Juan Pablo","family":"Cruz","sequence":"additional","affiliation":[{"name":"Departamento de Radiolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Bravo","sequence":"additional","affiliation":[{"name":"Departamento de Radiolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-1876","authenticated-orcid":false,"given":"Carolina","family":"Pelayo","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8143-4497","authenticated-orcid":false,"given":"Bernardita","family":"Soler","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Uribe-San-Martin","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-5433","authenticated-orcid":false,"given":"Ethel","family":"Ciampi","sequence":"additional","affiliation":[{"name":"Departamento de Neurolog\u00eda, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Neurology, Hospital S\u00f3tero del R\u00edo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_2_6_2","unstructured":"Protocolo 2019. Tratamiento de Segunda L\u00ednea Basado en Fingolimod o Natalizumab o Alemtuzumab o Cladribina u Ocrelizumab para personas con Esclerosis M\u00faltiple Recurrente Remitente con falla a tratamiento con inmunomoduladores y Tratamiento con Ocrelizumab para personas con Esclerosis M\u00faltiple Primaria Progresiva. Santiago Chile: Ministry of Health. https:\/\/leyricartesoto.minsal.cl\/storage\/Qeso5K5LGmMClfUuBTA3h0T86Lf1JohxymlH4X9W.pdf"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.188"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116973"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000719"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51282"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15142"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51732"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x-anp-2020-0339"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104794"},{"key":"e_1_3_2_16_2","volume-title":"2024 American Academy of Neurology annual meeting","author":"Amezcua L","unstructured":"Amezcua L, Monson N, Williams N, et al. One-year analysis of efficacy and safety data from Black\/African American and Hispanic\/Latino people with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial [Poster Abstract]. In: 2024 American Academy of Neurology annual meeting, April 2024, Denver, CO, USA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25688"},{"key":"e_1_3_2_18_2","first-page":"49","article-title":"Multiple sclerosis treatment in racial and ethnic minorities: Systematic literature review shows little evidence to guide treatment","volume":"2020","author":"Robers M","unstructured":"Robers M, Soneji D, Amezcua L. Multiple sclerosis treatment in racial and ethnic minorities: Systematic literature review shows little evidence to guide treatment. Pract Neurol 2020: 49\u201354.","journal-title":"Pract Neurol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103248"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_2_22_2","unstructured":"Roche H-L. A study of ocrelizumab in participants with relapsing-remitting multiple sclerosis (RRMS) who have had a suboptimal response to an adequate course of disease-modifying treatment (DMT) (Clinicaltrials.gov protocol no 0263; 7856). 2020 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02637856"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40940-w"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103690"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028833"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241269218"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241269219"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001275"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2022-003426"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241309835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585241309835","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241309835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:17:14Z","timestamp":1777695434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585241309835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/13524585241309835"],"URL":"https:\/\/doi.org\/10.1177\/13524585241309835","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}